Achillion Pharmaceuticals (NASDAQ:ACHN) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, ValuEngine reports.
A number of other research analysts have also recently issued reports on ACHN. BidaskClub raised Zai Lab from a “buy” rating to a “strong-buy” rating in a report on Friday, June 28th. Zacks Investment Research raised Investar from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Tuesday, June 4th. Finally, Barclays set a $24.00 price objective on Orion Engineered Carbons and gave the company a “hold” rating in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $2.75.
Shares of NASDAQ ACHN opened at $2.40 on Tuesday. The firm’s fifty day moving average is $2.74. Achillion Pharmaceuticals has a 52-week low of $1.29 and a 52-week high of $3.98.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.14). On average, equities research analysts anticipate that Achillion Pharmaceuticals will post -0.59 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Achillion Pharmaceuticals by 27.0% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,854 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 33,097 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Achillion Pharmaceuticals by 1.5% in the fourth quarter. BlackRock Inc. now owns 12,101,177 shares of the biopharmaceutical company’s stock valued at $19,241,000 after buying an additional 175,818 shares during the last quarter. Candriam Luxembourg S.C.A. raised its holdings in shares of Achillion Pharmaceuticals by 11.5% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 725,000 shares of the biopharmaceutical company’s stock valued at $1,153,000 after buying an additional 75,000 shares during the last quarter. 683 Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals in the fourth quarter valued at about $1,590,000. Finally, Geode Capital Management LLC raised its holdings in shares of Achillion Pharmaceuticals by 6.3% in the fourth quarter. Geode Capital Management LLC now owns 1,547,004 shares of the biopharmaceutical company’s stock valued at $2,459,000 after buying an additional 91,346 shares during the last quarter. 79.30% of the stock is owned by institutional investors and hedge funds.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Further Reading: What does a bar chart display?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.